Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
- Diabetes roundup. Greener, Mark // Independent Nurse;10/17/2016, p12
No abstract available.
- The ORIGIN Trial: Basal Insulin vs Standard Care for Early Type 2 Diabetes. Kuritzky, Louis // Hospital Medicine Alert;Oct2012 Clinical Bri, p19
No abstract available.
- The ORIGIN Trial: Basal Insulin vs Standard Care for Early Type 2 Diabetes. // Clinical Cardiology Alert;Oct2012 Clinical Briefs in Primary Care, p19
The article discusses the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial published in a 2012 issue of the "New England Journal of Medicine" which provides a comparison between the use of basal insulin and standard care for early type 2 diabetes patients.
- The clinical pharmacology of rapid-release formulation of bromocriptine -- a new antidiabetic drug. Kasznicki, Jacek; Mikolajczyk, Melania; Drzewoski, J�zef // Experimental & Clinical Diabetology / Diabetologia Doswiadczalna;2011, Vol. 11 Issue 2, p64
The article presents a pharmacological analysis of the antidiabetic ergot alkaloid drug bromocriptine in rapid release formulation as a treatment for non-insulin-dependent (type 2) diabetes. Bromocriptine regulates circadian rhythms of dopamine activity in the central nervous system (CNS)...
- Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study Ryuzo Kawamori; Koichi Node; Toshiaki Hanafusa; Yoshihito Atsumi; Yusuke Naito; Yoshitomo Oka // Cardiovascular Diabetology;2013, Vol. 12 Issue 1, p1
Background: The Cardiovascular Risk Evaluation in people with type 2 Diabetes on Insulin Therapy (CREDIT) study is an international, multicenter, observational study designed to assess metabolic parameters and cardiovascular risk of patients with type 2 diabetes mellitus (T2DM) on insulin...
- APWCA Case Study #2: Application of End-Diastolic Pneumatic Compression Therapy with the Circulator Boot. Filip, John // Podiatry Management;Nov/Dec2007, Vol. 26 Issue 9, p149
The article describes the case of a 73-year old Caucasian female who presented with multiple bilateral diabetic lower leg wounds. She was diagnosed with several peripheral vascular diseases, type-2 diabetes with non-ketotic hyperosmolar coma, and non-healing bilateral lower extremity diabetic...
- Reexamining Misconceptions About (Î²-Blockers in Patients With Diabetes. McGill, Janet B. // Clinical Diabetes;Winter2009, Vol. 27 Issue 1, p36
The article presents information on type 2 diabetes and hypertension, which are the most common contributors to cardiovascular disease in the U.S. It is stated that hypertension affects 20-60% of patients with diabetes. The authors' discusses the need for appropriate and aggressive therapy for...
- Concurrent Blood Pressure, Glycemic and Lipid Control for the Prevention of Vascular Complications of Type II Diabetes Mellitus: A Long Overdue Objective? Athyros, Vasilios G.; Mitsiou, Eydoxia K.; Tziomalos, Konstantinos; Karagiannis, Asterios; Mikhailidi, Dimitri P. // Current Vascular Pharmacology;Jan2010, Vol. 8 Issue 1, p1
The author focuses on various studies on the association between cardiovascular (CVD) events and diabetes. It notes that the objective of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, which started in 2001, is to identify the effect of intensive glucose lowering on CVD...
- Cardiovascular Disease Risk Factors Predict the
Development of Type 2 Diabetes. D'Agostino Jr., Ralph B.; Hamman, Richard F.; Karter, Andrew J.; Mykkanen, Leena; Wagenknecht, Lynne E.; Haffner, Steven M. // Diabetes Care;Sep2004, Vol. 27 Issue 9, p2234
Presents the study "Cardiovascular Disease Risk Factors Predict the Development of Type 2 Diabetes." Prevalence and incidence of type 2 diabetes in the U.S.; Ways to prevent type 2 diabetes; Results of the study.